Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Juarez, J. C.
Right arrow Articles by Doñate, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Juarez, J. C.
Right arrow Articles by Doñate, F.
Clinical Cancer Research Vol. 12, 4974-4982, August 15, 2006
© 2006 American Association for Cancer Research


Cancer Therapy: Preclinical

Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1

Jose C. Juarez1, Oscar Betancourt, Jr.1, Steven R. Pirie-Shepherd1, Xiaojun Guan1, Melissa L. Price1, David E. Shaw2, Andrew P. Mazar1 and Fernando Doñate1

Authors' Affiliations: 1 Attenuon, LLC, San Diego, California and 2 D.E. Shaw Research and Development, LLC, New York, New York

Requests for reprints: Andrew P. Mazar, Attenuon, LLC, 11535 Sorrento Valley Road, San Diego, CA 92121. Phone: 858-622-0510; Fax: 858-622-0517; E-mail: mazar{at}attenuon.com.

Purpose: A second-generation tetrathiomolybdate analogue (ATN-224; choline tetrathiomolybdate), which selectively binds copper with high affinity, is currently completing two phase I clinical trials in patients with advanced solid and advanced hematologic malignancies. However, there is very little information about the mechanism of action of ATN-224 at the molecular level.

Experimental Design: The effects of ATN-224 on endothelial and tumor cell growth were evaluated in cell culture experiments in vitro. The antiangiogenic activity of ATN-224 was investigated using the Matrigel plug model of angiogenesis.

Results: ATN-224 inhibits superoxide dismutase 1 (SOD1) in tumor and endothelial cells. The inhibition of SOD1 leads to inhibition of endothelial cell proliferation in vitro and attenuation of angiogenesis in vivo. The inhibition of SOD1 activity in endothelial cells is dose and time dependent and leads to an increase in the steady-state levels of superoxide anions, resulting in the inhibition of extracellular signal-regulated kinase phosphorylation without apparent induction of apoptosis. In contrast, the inhibition of SOD1 in tumor cells leads to the induction of apoptosis. The effects of ATN-224 on endothelial and tumor cells could be substantially reversed using Mn(III)tetrakis(4-benzoic acid)porphyrin chloride, a catalytic small-molecule SOD mimetic.

Conclusions: These data provide a distinct molecular target for the activity of ATN-224 and provide validation for SOD1 as a target for the inhibition of angiogenesis and tumor growth.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. L. Turski and D. J. Thiele
New Roles for Copper Metabolism in Cell Proliferation, Signaling, and Disease
J. Biol. Chem., January 9, 2009; 284(2): 717 - 721.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. A. Lowndes, A. Adams, A. Timms, N. Fisher, J. Smythe, S. M. Watt, S. Joel, F. Donate, C. Hayward, S. Reich, et al.
Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors
Clin. Cancer Res., November 15, 2008; 14(22): 7526 - 7534.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. C. Juarez, M. Manuia, M. E. Burnett, O. Betancourt, B. Boivin, D. E. Shaw, N. K. Tonks, A. P. Mazar, and F. Donate
Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling
PNAS, May 20, 2008; 105(20): 7147 - 7152.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. P. Fruehauf and F. L. Meyskens Jr.
Reactive Oxygen Species: A Breath of Life or Death?
Clin. Cancer Res., February 1, 2007; 13(3): 789 - 794.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.